Table 2.
Vaccination coverage.
| Vaccines | Vaccination coverage total sample | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | 95% CI | N | % | 95% CI | N | % | 95% CI | |
| Flu | 1718/2072 | 83.0 | (81.2–84.5) | 878/1043 | 84.2 | (82–86.3) | 842/1029 | 81.9 | (79.4–84.1) |
| Pneumococcus polysaccharide | 480/2072 | 23.2 | (21.4–25) | 249/1043 | 23.9 | (21.4–26.6) | 232/1029 | 22.5 | (20.1–25.2) |
| Pneumococcus conjugate | 1029/2072 | 49.7 | (47.5–51.8) | 551/1043 | 52.8 | (49.8–55.8) | 480/1029 | 46.6 | (43.6–49.7) |
| Herpes zoster | 429/2072 | 20.7 | (19–22.5) | 231/1043 | 22.1 | (19.7–24.8) | 198/1029 | 19.2 | (17–21.8) |
| Hepatitis B | 66/2072 | 3.18 | (2.5–4.03) | ||||||
| Td vax adult | 64/2072 | 3.1 | (2.4–3.9) | ||||||
| Tdap-IPV | 25/2072 | 1.2 | (0.81–1.78) | ||||||
| Tetanus monovalent | 62/2072 | 3.0 | (2.3–3.8) | ||||||